The deal is expected to expand Thermo’s ability to detect infectious diseases such as the new coronavirus.
Thermo CEO Marc Casper said the deal will help the company broaden its business from scientific discovery to diagnostics.
Qiagen makes life science and molecular diagnostic equipment. The company has more than 5,000 employees and 35 locations in 25 countries. It had a revenue of $1.53 billion last year.
The deal is expected to close in the first half of next year.
Read the full news release here.
More articles on supply chain:
US health systems are running out of protective face masks
6 common supply chain errors
Top 5 supply chain stories in February
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
